Type 2 diabetes and fractures: More information is needed

Endocrine

Volumn 43, Issue 3, 2013, Pages 469-471

  Rubin, Mishaela R ^a  

^a Columbia University ^*  (United States)

Author keywords

Bone mineral density; Bone quality; Diabetes; Fracture prediction

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ADVANCED GLYCATION END PRODUCT; PARATHYROID HORMONE; SCLEROSTIN; VITAMIN D;

BONE DENSITY; BONE FRAGILITY; COMPUTER ASSISTED TOMOGRAPHY; CORTICAL BONE; DISEASE ASSOCIATION; DISEASE SEVERITY; DUAL ENERGY X RAY ABSORPTIOMETRY; EDITORIAL; FALLING; FRACTURE; FRAGILITY FRACTURE; HIP FRACTURE; HUMAN; MUSCULOSKELETAL SYSTEM PARAMETERS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; POSTMENOPAUSE; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SCORING SYSTEM; SPINAL DEFORMITY INDEX; TRABECULAR BONE SCORE;

EID: 84877874659     PISSN: 1355008X     EISSN: 15590100     Source Type: Journal    
DOI: 10.1007/s12020-013-9901-6     Document Type: Editorial

References (15)

1. IDF Diabetes Atlas Update 2012. http://www.idf.org/diabetesatlas/5e/ Update2012. Accessed 10 Jan 2013
2. M. Janghorbani, R.M. Van Dam, W.C. Willett, F.B. Hu, Systematic review of type 1 and type 2 diabetes mellitus and risk of fracture. Am. J. Epidemiol. 166(5), 495-505 (2007). doi: 10.1093/aje/kwm106
3. P. Vestergaard, Discrepancies in bone mineral density and fracture risk in patients with type 1 and type 2 diabetes: a meta-analysis. Osteoporos. Int. 18(4), 427-444 (2007). doi: 10.1007/s00198-006-0253-4
4. A.V. Schwartz, E. Vittinghoff, D.C. Bauer, T.A. Hillier, E.S. Strotmeyer, K.E. Ensrud, M.G. Donaldson, J.A. Cauley, T.B. Harris, A. Koster, C.R. Womack, L. Palermo, D.M. Black, Association of BMD and FRAX score with risk of fracture in older adults with type 2 diabetes. JAMA 305(21), 2184-2192 (2011). doi: 10.1001/jama.2011.715
5. L.M. Giangregorio, W.D. Leslie, L.M. Lix, H. Johansson, A. Oden, E. McCloskey, J.A. Kanis, FRAX underestimates fracture risk in patients with diabetes. J. Bone Miner. Res. 27(2), 301-308 (2012). doi: 10.1002/jbmr.556
6. D.E. Bonds, J.C. Larson, A.V. Schwartz, E.S. Strotmeyer, J. Robbins, B.L. Rodriguez, K.C. Johnson, K.L. Margolis, Risk of fracture in women with type 2 diabetes: the Women's Health Initiative Observational Study. J. Clin. Endocrinol. Metab. 91(9), 3404-3410 (2006). doi: 10.1210/jc.2006-0614
7. C. Di Somma, M. Rubino, A. Faggiano, L. Vuolo, P. Contaldi, N. Tafuto, M. Andretti, S. Savastano, A. Colao, Spinal deformity index in patients with type 2 diabetes. Endocrine (2012). doi: 10.1007/s12020-012-9848-z
8. H.K. Genant, C.Y. Wu, C. van Kuijk, M.C. Nevitt, Vertebral fracture assessment using a semiquantitative technique. J. Bone Miner. Res. 8(9), 1137-1148 (1993). doi: 10.1002/jbmr.5650080915
9. T. Mancini, G. Mazziotti, M. Doga, R. Carpinteri, N. Simetovic, P.P. Vescovi, A. Giustina, Vertebral fractures in males with type 2 diabetes treated with rosiglitazone. Bone 45(4), 784-788 (2009). doi: 10.1016/j.bone.2009.06.006
10. D. Hans, A.L. Goertzen, M.A. Krieg, W.D. Leslie, Bone microarchitecture assessed by TBS predicts osteoporotic fractures independent of bone density: the Manitoba study. J. Bone Miner. Res. 26(11), 2762-2769 (2011). doi: 10.1002/jbmr.499
11. W.D. Leslie, O. Lamy, D. Hans, Trabecular bone score (TBS) is more sensitive than BMD to diabetes-related fracture risk. J. Bone Miner. Res. (2012). http://www.asbmr.org/Meetings/AnnualMeeting/AbstractDetail.aspx?aid= be138477-dbd7-49d3-9e3c-318d6b4d6a49
12. J.M. Patsch, A.J. Burghardt, S.P. Yap, T. Baum, A.V. Schwartz, G.B. Joseph, T.M. Link, Increased cortical porosity in type-2 diabetic postmenopausal women with fragility fractures. J. Bone Miner. Res. 28(2), 313-324 (2012). doi: 10.1002/jbmr.1763
13. S.Y. Tang, M.R. Allen, R. Phipps, D.B. Burr, D. Vashishth, Changes in non-enzymatic glycation and its association with altered mechanical properties following 1-year treatment with risedronate or alendronate. Osteoporos. Int. 20(6), 887-894 (2009). doi: 10.1007/s00198-008-0754-4
14. A. Garcia-Martin, P. Rozas-Moreno, R. Reyes-Garcia, S. Morales-Santana, B. Garcia-Fontana, J.A. Garcia-Salcedo, M. Munoz-Torres, Circulating levels of sclerostin are increased in patients with type 2 diabetes mellitus. J. Clin. Endocrinol. Metab. 97(1), 234-241 (2012). doi: 10.1210/jc.2011-2186
15. C. Hamann, M. Rauner, Y. Hohna, R. Bernhardt, J. Mettelsiefen, C. Goettsch, K.P. Gunther, M. Stolina, C.Y. Han, F.J. Asuncion, M.S. Ominsky, L.C. Hofbauer, Sclerostin antibody treatment improves bone mass, bone strength, and bone defect regeneration in rats with type 2 diabetes mellitus. J. Bone Miner. Res. (2012). doi: 10.1002/jbmr.1803